[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608424":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":17,"centralContacts":22,"locations":32,"responsibleParty":51,"collaborators":54,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":7,"enrollmentInfo":68,"targetDuration":7,"studyType":71,"phases":7,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":35,"whyStopped":7,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Dartmouth-Hitchcock Medical Center","OTHER",null,[9,13],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Ameluz 10% Topical Gel","One-time topical application of 10% Ameluz gel for up to 1 hour",{"type":14,"name":15,"description":16,"armGroupLabels":7,"otherNames":7},"DEVICE","Protoporphyrin IX","Tissue oxygen imaging using protoporphyrin IX (PIX), a non-significant risk device.",[18],{"name":19,"affiliation":20,"role":21},"Michael Chapman, MD","Dartmouth","PRINCIPAL_INVESTIGATOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":7,"email":27},"Dylan L Parker, MD","CONTACT","603-653-2209","Dylan.J.Parker@Hitchcock.org",{"name":29,"role":25,"phone":30,"phoneExt":7,"email":31},"Staci Shaw","603-650-3693","Staci.L.Shaw@Hitchcock.org",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Dartmouth Hitchcock","RECRUITING","Lebanon","New Hampshire","03766","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-72.25176,43.64229,{"lat":45,"lon":44},[48],{"name":49,"role":25,"phone":50,"phoneExt":7,"email":27},"Dylan Parker, MD","6036532209",{"type":21,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Michael S. Chapman","Principal Investigator",[55],{"name":56,"class":6},"Dartmouth College","100608424","assessment-of-skin-lesions-using-a-tissue-oxygen-imager-based-on-protoporphyrin-ix-ppix-fluorescence-this-is-an-open-label-non-randomized-feasibility-study-that-includes-a-one-time-application-of-an-fda-approved-medication-followed-by-local-imaging-for-benign-skin-growth-and-lesions-clinically-100608424",false,"NCT07201376","Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically","Tissue Oxygen Imager","PPIX","Inclusion Criteria:\n\n* Adults ≥ 18 years of age.\n* Histologic proof of non-melanoma skin cancer. Patients with different skin tones based on the Fitzpatrick Scale, who present with skin growth or lesions and are scheduled for resection.\n* As determined by the enrolling physician or study team member, the patient must have the willingness and ability to understand and comply with study procedures.\n* Women of childbearing potential (WOCBP): Premenopausal females who had at least one menstrual cycle in the past 12-months and capable to become pregnant, must have a negative serum beta-HCG pregnancy test result within seven days prior to start of study.\n* Lesions must measure between 5 mm and 3 cm in diameter.\n\nExclusion Criteria:\n\n* Patients who are \\\u003C18 years of age\n* Adults who are unable to provide informed consent.\n* Known allergy to Ameluz\n* Photosensitivity or photodermatoses or similar conditions.\n* Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and\u002For comply with study protocol, in the opinion of the investigator\n* Known hypersensitivity to porphyrins or to any component of Ameluz, including soya bean phosphatidylcholine.\n* Females who are currently breast-feeding",true,"ALL","18 Years",{"count":69,"type":70},125,"ESTIMATED","OBSERVATIONAL","The primary objective of this study is the evaluation of the efficacy of the tissue oxygen imager based on PpIX DF in differentiating benign skin growth from non-melanoma skin cancer (NMSC).",[74,75],"Non-Melanoma Skin Cancer (NMSC)","Benign Skin Growth",[75,77],"Non-Melanoma Skin Cancer","2026-02-04",{"date":80,"type":81},"2026-02-06","ACTUAL",{"date":83,"type":81},"2025-11-14",{"date":85,"type":70},"2027-11",{"name":5,"class":6},1]